Patent 11254726 was granted and assigned to A2 Biotherapeutics, Inc on February, 2022 by the United States Patent and Trademark Office.
Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.